BioNTech Investor Day Presentation Deck

Strong momentum built on two decades of innovation 2014 Mid 1990s Start of mRNA vaccine research by founders 2008 BioNTech founding By Ugur Sahin, Özlem Türeci, and Christoph Huber in Mainz, Germany 2005 First mRNA patents Published 2006 in Blood Individualized mRNA cancer vaccine first-in-human trial 2013 Off-the-shelf mRNA vaccine first-in-human trial Published 2017 in Nature 2015 Nanoparticle mRNA vaccine first in-human trial Published 2016 in Nature 2017 Individualized mRNA vaccine reduces metastatic relapse rate in melanoma patients published in Nature ¹ IVAC trial with extension of relapse. free survival 2016 Pre-clinical proof-of-concept of RNA-lipoplex treatment 2020 2021 2022 Project Lightspeed COVID-19 vaccine Improved initiated full FDA approval2 Small molecule immuno-modulator first-in-human trial CARVac pre-clinical proof-of-concept published in Science. 2019 NASDAQ Initial Public Offering Bispecifics first-in-human trial³ 7 clinical programs MS, multiple sclerosis. 1 iNeST collaboration with Genentech; 2 Global co-development co-commercial agreement with Pfizer; ³ GEN1046 collaboration with Genmab. RiboCytokine first-in-human trial MS vaccine pre- clinical proof-of- concept published in Science COVID-19 vaccine formulation launch Cell therapy first-in-human trial Variant-adapted COVID-19 vaccine submission RiboMab first-in-human trial for BNT211 PRIME designation Adjuvant pancreatic data presented at ASCO annual meeting 17 clinical programs BIONTECH 10

View entire presentation